Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...
Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...
As co-hosts of the 2026 FIFA World Cup, the United States are set to embark on one of the most important months in men's national team history. Led by Mauricio Pochettino, the USMNT is gearing up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback